The Oasmia Annual Report for the fiscal year 2011/2012 is now available at the company website www.vivesto.com.
The Corporate Governance report for the fiscal year 2011/2012 is also available at the company website www.vivesto.com.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company share is listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange.